3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Vomiting
2
Ventilator-Induced Lung Injury
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Substance-Related Disorders
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Postoperative Complications
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Opioid-Related Disorders
1
Opioid-Induced Constipation
1
Neoplasms
1
Motor Activity
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Cancer Pain
1
Breast Neoplasms
1
Agnosia
1
Acromegaly
1
Interventions
Docetaxel
171
Radiotherapy
144
Magnetic Resonance Spectroscopy
142
Leuprolide
112
Prednisone
108
enzalutamide
102
Radiosurgery
101
Abiraterone Acetate
94
Androgen Antagonists
91
Goserelin
83
bicalutamide
81
gallium 68 PSMA-11
70
Surveys and Questionnaires
63
apalutamide
57
Specimen Handling
56
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
55
Radiation
47
Gonadotropin-Releasing Hormone
45
Standard of Care
44
Biopsy
44
Brachytherapy
42
Radiotherapy, Intensity-Modulated
40
Blood Specimen Collection
40
darolutamide
39
abiraterone
39
cabazitaxel
35
Exercise
35
Carboplatin
33
Pluvicto
32
Triptorelin Pamoate
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms
×
Dosage Forms
×
Clear all
NCT00913068
2021-10-04
TAP
Nova Scotia Health Authority
Phase NA
Completed
110 enrolled
5 charts